Skip to main content

Cancer epigenetics

Cancer epigenetics: from laboratory studies and clinical trials to precision medicine





Epigenetic dysregulation is a common feature of a myriad of human diseases, particularly cancer. Defining the epigenetic defects associated with malignant tumors has become a focus of cancer research resulting in the gradual elucidation of cancer cell epigenetic regulation. In fact, most stages of tumor progression, including tumorigenesis, promotion, progression, and recurrence are accompanied by epigenetic alterations, some of which can be reversed by epigenetic drugs. The main objective of epigenetic therapy in the era of personalized precision medicine is to detect cancer biomarkers to improve risk assessment, diagnosis, and targeted treatment interventions. Rapid technological advancements streamlining the characterization of molecular epigenetic changes associated with cancers have propelled epigenetic drug research and development. This review summarizes the main mechanisms of epigenetic dysregulation and discusses past and present examples of epigenetic inhibitors in cancer diagnosis and treatment, with an emphasis on the development of epigenetic enzyme inhibitors or drugs. In the final part, the prospect of precise diagnosis and treatment is considered based on a better understanding of epigenetic abnormalities in cancer.
Facts

Epigenetic regulatory mechanisms involve cancer biology, especially DNA methylation, histone acetylation, and miRNAs.

The expression of tumor-related genes is closely related to the epigenetic regulatory process of tumors.

DNMTi, HDACis, BETis and other epigenetic therapies are constantly being updated and used in the clinic.

Epigenetic combination therapy is a promising direction.

Multi-omics, gene therapy, and AI are favorable transitions from epigenetic therapy to precision medicine.

Mechanisms of epigenetic dysregulation in cancer

Epigenetics is defined as a series of biological processes involving chromatin-mediated DNA template regulation, independent of changes in the original DNA sequence. Protein complexes that control epigenetic modifications (including DNA methylation and covalent histone modification) can be divided into writers, readers, and erasers. Epigenetic writers add distinct epigenetic chemical modifications to DNA or histones in the form of epigenetic markers. Readers are methyl-CpG-binding domain proteins (MBPs) that identify and interpret the specialized domains of modified proteins. Chromatin-modifying enzymes function as erasers by removing epigenetic markers. Epigenetic dysregulation, including DNA, RNA methylation defects and abnormal post-translational modification processes, is commonly associated with all cancer types.
Fig. 1: Epigenetic alterations associated with carcinogenesis.


Epigenetic alterations involve DNA methylation, histone acetylation, and miRNA regulation that have reversible effects on gene silencing and activation through epigenetic enzymes and related proteins. Writers (DNMT, HAT, and KMT) are enzymes that add acetyl (Ac) and methyl (Me) tags to histones. MBDs are readers that recognize methyl-CpG and modify histones. Erasers (DNA demethylase, HDAC, and KDM) are responsible for removing chemical groups from DNA or histones. Noncoding RNAs (miRNAs and lncRNAs) are also involved in epigenetic regulation. A DNA methylation in normal and cancer cells. The overall hypomethylation and local hypermethylation of promoter regions are characteristics of cancer cells. P: promoter region. B Methylation and demethylation of lysine or arginine in histones. Lysine can be methylated once (me1), twice (me2) or three times (me3) catalyzed by KMT. Arginine is methylated once (me1) or twice (me2) catalyzed by KMT. These processes can be reversed by KDM. C HDAC removes acetyl groups from histone lysine residues. Acetylated histones are considered “active chromatin” allowing gene transcription, whereas deacetylated histones are “non-active chromatin” associated with gene silencing. D The methylation of m6A is installed by the RNA methyltransferase complex with the catalytic subunit METTL3/METTL4 (writer) and removed by demethylases, such as FTO and ALKBH5 (eraser). m6A reader proteins (YTHDCs) can specifically bind m6A transcripts. DNMT, DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; KDM, lysine demethylase; KMT, lysine methyltransferase; m6A, N6-Methyladenosine. MBP, methyl-CpG-binding domain protein.

epigenetics, drugs, gene expression, histone modifications, DNA methylation, non-coding RNAs, cancer, genetic disorders, small molecules, gene therapies, CRISPR, off-target effects, tissue delivery, drug specificity, epigenome, restoration, clinical applications, molecular therapies, gene regulation, pharmacological interventions, biomarkers, therapeutic targets, precision medicine, therapeutic efficacy, drug resistance, epigenetic regulation, targeted therapies.
#epigenetics, #drugs, #geneexpression, #histonemodifications, #DNAmethylation, #noncodingRNAs, #cancer, #geneticdisorders, #smallmolecules, #genetherapies, #CRISPR, #offtargeteffects, #tissuedelivery, #drugspecificity, #epigenome, #restoration, #clinicalapplications, #moleculartherapies, #generegulation, #pharmacologicalinterventions, #biomarkers, #therapeutictargets, #precisionmedicine, #therapeuticefficacy, #drugresistance, #epigeneticregulation, #targetedtherapies.

International Conference on Genetics and Genomics of Diseases 

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...